Latest news

• Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

  Final decision due by 18 October. A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the US Food and Drug Administration (FDA), with ... The co-formulation of two of Roche’s blockbuster breast cancer

• AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

  Enhertu is one of a crop of new HER2-targeting drugs that aim to challenge Roche’s long-dominant position in HER2-positive breast cancer with its triumvirate of Herceptin (trastuzumab), ... s chemotherapy Xeloda (capecitabine) in patients previously

• EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

  cancer cells despite treatment before surgery with taxane and other  HER2 drugs like Roche’s Herceptin (trastuzumab). ... in patients previously treated with Roche’s trio of HER2 drugs.

• AZ, Daiichi Sankyo strengthen case for HER2 candidate

  Its nearest rival in the area is Roche’s anti-HER2 ADC Kadcyla (trastuzumab emtansine). ... Both drugs work by combining the HER2-targeting of trastuzumab with a cell-killing chemotherapy component designed to improve its ability to kill breast cancer

• Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

  a HER2-targeting drug for breast cancer that was  licensed by AstraZeneca for $1.35bn upfront earlier this year. ... warrant HER2-targeted drugs.